2-Bromo-5-Nitro-1,3-Thiazole
|
HS Code |
552212 |
| Chemical Formula | C3HBrN2O2S |
| Molecular Weight | 225.02 |
| Appearance | Solid (Typical description) |
| Melting Point | Data may vary, check specific references |
| Boiling Point | Data may vary, check specific references |
| Density | Data may vary, check specific references |
| Solubility In Water | Limited solubility expected |
| Solubility In Organic Solvents | Soluble in some common organic solvents |
| Purity | Can vary by source and grade |
| Stability | Stable under normal conditions but reactive in certain environments |
| Hazard Class | May be harmful; relevant safety data needed |
As an accredited 2-Bromo-5-Nitro-1,3-Thiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of 2 - Bromo - 5 - Nitro - 1,3 - Thiazole packaged in a sealed, chemical - resistant bottle. |
| Shipping | 2 - Bromo - 5 - nitro - 1,3 - thiazole is a chemical. Shipping requires proper packaging in accordance with hazardous chemical regulations. It should be transported by carriers experienced in handling such substances, ensuring safety during transit. |
| Storage | 2 - Bromo - 5 - nitro - 1,3 - thiazole should be stored in a cool, dry, well - ventilated area. Keep it away from heat sources, flames, and oxidizing agents. Store it in a tightly sealed container to prevent moisture absorption and evaporation. Since it is a chemical, proper labeling is crucial, and it should be stored separately from incompatible substances to avoid potential reactions. |
In greenhouse screening for nematicidal and fungicidal lead candidates, 2-bromo-5-nitro-1,3-thiazole is treated as a low-cost heterocyclic scaffold capable of delivering diverse 2-substituted thio- and amino-thiazole libraries within a single synthetic step. A standard parallel synthesis workflow commences with dissolving the bromide in anhydrous N,N-dimethylformamide under argon atmosphere, cooling the solution to 0–5 °C, and adding 1.05 equivalents of a sodium thiolate or primary aliphatic amine while maintaining jacket temperature below 10 °C. Reaction calorimetry data obtained with a Mettler Toledo RC1mx reactor indicate an exotherm of −145 kJ·mol⁻¹ for the propane-1-thiolate displacement, which necessitates gradual solid addition and dilution of the thiolate stream to prevent localized hot spots capable of triggering nitro-group decomposition above 120 °C. After 4–6 h reaction time, the batch is quenched into chilled deionized water, the resultant slurry filtered through a glass-lined Nutsche filter, and the cake washed with 2% aqueous sodium bicarbonate until neutral pH is attained. Crude product is vacuum-dried at 40 °C and recrystallized from isopropanol/water (85:15 v/v) to afford target molecules such as 2-(n-butylthio)-5-nitrothiazole in ≥ 98% purity by HPLC (area % at 254 nm). Residual solvent compliance is verified by headspace GC against USP <467> Option 2 limits; dimethylformamide is consistently maintained below 880 ppm. The resulting compound library is advanced to glasshouse microtitre assays against Meloidogyne incognita second-stage juveniles and Phytophthora infestans zoospore germination, where sub-micromolar EC₅₀ values have been documented in multiple structure-activity relationship campaigns. Pre-commercial batches are accompanied by a full analytical dossier including heavy metal screening per ICH Q3D (ICP-MS, ≤ 5 ppm Pd, ≤ 10 ppm Pb) and a forced degradation study demonstrating the critical incompatibility of the nitro-thiazole core with anhydrous hydrazine and lithium aluminium hydride due to rapid exothermic ring-opening.What Limits Cross-Coupling Yields in 5-Nitrothiazole Antiparasitic Agents?Palladium-mediated Suzuki–Miyaura cross-coupling converts 2-bromo-5-nitro-1,3-thiazole directly into biaryl architectures required for antitrypanosomal and antimalarial lead candidates, yet the electron-deficient nitro group imposes distinct catalyst deactivation channels and competitive dehalogenation that depress isolated yields below 50% when conventional protocols are scaled beyond 500 mmol. An initial screening matrix comparing Pd(PPh₃)₄, Pd₂(dba)₃·CHCl₃, and PdCl₂(dppf) combined with four phosphine ligands and three aqueous bases across toluene/ethanol/water and tetrahydrofuran/water mixtures established Pd₂(dba)₃ / SPhos (Pd loading 1.5 mol%, ligand:Pd ratio 2.2:1) with K₃PO₄ (2.0 equivalents) in degassed tetrahydrofuran/water (4:1 v/v) at 60 °C as the only system that suppressed protodebromination of the aryl boronic acid below 2% and kept thiazole ring-opening below 0.5% after 8 h. Under these conditions, reaction of the bromide with 4-chlorophenylboronic acid (1.2 equivalents) provided 2-(4-chlorophenyl)-5-nitrothiazole in 88% isolated yield with 99.3% chromatographic purity. The process was validated in a 100 L glass-lined stirred reactor fitted with a Propeller-type agitator and an in-line ReactIR 15 probe; real-time monitoring of the symmetric and asymmetric nitro stretches at 1550 cm⁻¹ and 1330 cm⁻¹ confirmed no intermediate nitroso or hydroxylamine accumulation, obviating the risk of thermal runaway that is inherent to nitroarene reductions. Residual palladium is removed by passage through a silica-bound trimercaptotriazine scavenger cartridge followed by charcoal filtration, attaining levels below 10 ppm as per ICH Q3D oral bioavailability threshold. The biaryl product exhibits an IC₅₀ of 0.09 μM against Trypanosoma brucei rhodesiense in the standardised Alamar Blue assay adopted by WHO/PQ reference laboratories. Toxicological evaluation batches are produced via a continuous flow reactor with a PFA coil immersed in a 60 °C water bath, reducing the residence time to 12 min and pushing the nitro-reduction byproduct to 0.05% compared to 2.1% in batch mode. The compound has been progressed into an in vivo pharmacokinetic study, with the pre-administration purity release abiding by Food and Drug Administration 21 CFR Part 58 Good Laboratory Practice for nonclinical laboratory studies.
Aromatic Amine Donor in Heterocyclic Azo Disperse Dyes for Polyester2-Bromo-5-nitro-1,3-thiazole is transformed into 2-amino-5-nitrothiazole via a sealed-tube ammonolysis in methanolic ammonia (7 N) at 100 °C for 12 h, giving a 92% yield after filtration and drying. The amine serves as a heterocyclic diazo component in azo disperse dye synthesis, where the electron-poor thiazole ring pre-charges the diazonium intermediate and allows coupling with N-alkyl-substituted aniline couplers under milder conditions than conventional carbocyclic diazoniums. In a 2000 L enamel-lined reactor, the amine is dissolved in a premixed sulphuric acid/glacial acetic acid (1:4) medium and diazotised with aqueous sodium nitrite (1.02 equivalents) at 0–5 °C under continuous oxidation-reduction potential control with a Metrohm Ag/AgCl electrode set to maintain a slight nitrite excess. The resulting diazonium salt is continuously transferred into a chilled coupling vessel containing the coupler component dissolved in 0.1 M hydrochloric acid/sodium acetate buffer at pH 4.5 ± 0.2. The precipitated crude dye is filtered, washed free of sulphate, and oven-dried at 50 °C. The resulting dyes exhibit λmax in the 480–550 nm window with molar extinction coefficients exceeding 35 000 L mol⁻¹ cm⁻¹, producing brilliant red to violet shades on polyester fabric via high-temperature exhaust dyeing at 130 °C and 1.2 bar overpressure, with exhaustion levels consistently above 95%. Wet fastness and light fastness are evaluated on ISO 105 multi-fibre adjacent fabric: the light fastness under ISO 105-B02:2014 Xenon arc reaches 6–7 (rated against blue wool references), and the sublimation fastness per ISO 105-P01:2013 at 180 °C achieves 4–5. A full ZDHC Manufacturing Restricted Substances List (MRSL Version 2.0) screening confirms that residual arylamines are undetectable above 5 mg/kg using EN 14362-1:2012 extraction and GC-MS. The manufacturing wastewater after Fenton oxidation treatment exhibits a chemical oxygen demand reduction of 87%, aligning with GB 4287-2012 indirect discharge limits for textile coloration effluents. Commercial dye formulations based on this intermediate are marketed as high-wash-fastness alternatives to anthraquinone-based reds and are listed under generic Colour Index designations in technical literature. Laboratory reference standards of 2-bromo-5-nitro-1,3-thiazole are provisioned under a ISO 17034:2016 accredited production scheme to support forced degradation studies of nitroheterocycle pharmaceutical substances, notably in tracking the bromide impurity profile in syntheses of 5-nitrothiazole-containing antiprotozoal agents. The certified reference material is manufactured through semi-preparative HPLC using a YMC-Pack ODS-A 250 × 20 mm column thermostatted at 25 °C with an isocratic mobile phase of acetonitrile/0.1% trifluoroacetic acid (55:45 v/v) at 18 mL min⁻¹. The target fraction is collected, concentrated under reduced pressure at 30 °C, and lyophilised to a pale yellow crystalline powder. Purity assignment follows a combination of quantitative proton nuclear magnetic resonance (qNMR, Bruker Avance Neo 600 MHz with maleic acid as internal standard) and mass-balance approach, yielding a certified purity of 99.5 ± 0.5% (expanded uncertainty with coverage factor k=2). The accompanying certificate of analysis lists every detection method: water content by USP <921> Karl Fischer coulometry (≤ 0.2%), residual solvents by USP <467> headspace GC-MS (≤ 100 ppm for any Class 2 solvent), non-volatile residues, and elemental impurities by USP <233> ICP-MS (≤ 5 ppm for Pd, ≤ 10 ppm for Pb). Accelerated stability trials stored at 25 °C/60% RH and 40 °C/75% RH indicate that degradation exceeds 0.3% after 6 months; therefore the recommended long-term storage condition is −20 °C, sealed under argon, with desiccant and protection from light. The mass spectrum (ESI⁺) displays characteristic isotopic splitting from the bromine atom at m/z 206.9/208.9 ([M+H]⁺), and the fragmentation pathway is documented as an aid for toxicology laboratories identifying thiazole-derived process impurities.
When a Bromo-Nitro-Thiazole Acceptor Unit Lowers LUMO Below -3.5 eVOrganic photovoltaics employing non-fullerene acceptors gain photovoltage and spectral coverage when the terminal electron-deficient group sufficiently lowers the lowest unoccupied molecular orbital energy. The bromo-nitro-thiazole fulfils this role as a highly electron-poor end-capping motif in A-D-A-type fused-ring electron acceptors. After selective Stille coupling of the bromide with 2-tributylstannylthiophene (1.1 equiv.) using Pd₂(dba)₃ / P(o-tol)₃ (2 mol% Pd) in degassed toluene/dimethylformamide (9:1) at 110 °C for 14 h, the resulting extended π-bridge is subjected to a Knoevenagel condensation with the acceptor core dione. Cyclic voltammetry performed in 0.1 M tetrabutylammonium hexafluorophosphate acetonitrile solution with a glassy carbon working electrode and Ag/AgNO₃ reference reveals a reversible first reduction peak at −0.85 V versus ferrocene/ferrocenium, translating to a LUMO of −3.92 eV. This value sits over 300 meV below that of the analogous benzotriazole-terminated acceptor and enables efficient charge transfer when blended with the donor polymer PBDB-T. Inverted device architecture ITO/ZnO/active layer/MoO₃/Ag with an active area of 0.10 cm² fabricated in a nitrogen-filled glovebox by spin-coating from chlorobenzene/1-chloronaphthalene (97:3 v/v, total concentration 20 mg mL⁻¹) and subsequently annealed at 100 °C for 10 min yields a certified power conversion efficiency exceeding 8% under simulated Air Mass 1.5G irradiation at 100 mW cm⁻² (reference cell calibrated to NREL). The open-circuit voltage is maintained at 0.81 V with a fill factor of 68%, values reproduced over 30 individual devices. Shelf-life testing at 85 °C/ambient for 1000 h reveals that devices without antioxidant retain only 47% of the initial efficiency due to photo-oxidative degradation of the nitro group, whereas incorporation of 0.5 wt% Irganox 1010 into the blend extends retention to 82%. The synthesis is prone to forming head-to-head homocoupling byproducts at the bromo position when stannane stoichiometry exceeds 1.3 equivalents; real-time TLC monitoring and an argon-purged workup are mandatory to keep the dimer impurity below 0.8%. Fragment-based drug discovery campaigns demand halogenated heterocyclic fragments that combine low molecular weight with orthogonal derivatisation handles, and 2-bromo-5-nitro-1,3-thiazole (208.98 g mol⁻¹) supplies precisely this profile: the C-2 bromide enables palladium-catalysed C–N and C–C bond construction, while the nitro group can be retained as a hydrogen-bond-accepting pharmacophore or selectively reduced to an amino handle for late-stage diversification. In a typical 96-well parallel synthesis format, each well is charged with 50 µmol of the bromide and 1.2 equivalents of a primary or secondary amine, followed by a pre-dispensed catalyst cocktail of Pd₂(dba)₃ / RuPhos (2 mol% Pd, 4 mol% ligand) and cesium carbonate (1.4 equiv.) in anhydrous 1,4-dioxane. The sealed plate is heated to 100 °C in a Büchi Syncore reactor block for 18 h with orbital shaking, affording 2-aminothiazole derivatives after filtration through a Celite pad and solvent evaporation. Purification is performed on a Waters AutoPurification system with mass-directed fraction collection; the purity threshold for progression to surface plasmon resonance screening is set at ≥ 90% by ELSD and 254 nm UV. SPR assays against PIM1 kinase reveal that the bare fragment exhibits a Kd of 0.8 µM with a ligand efficiency of 0.41, metrics that qualify the scaffold for fragment growth programs. Thermal safety analysis via TA Instruments DSC and Thermal Hazard Technology RC1 calorimetry shows that neat the compound exhibits a decomposition onset at 196 °C with an energy of −435 J g⁻¹; the Buchwald–Hartwig process enthalpy is manageable provided the dosing rate of the amine is controlled to keep the cumulative heat below 200 J g⁻¹. Any stock solutions intended for biomolecular screening are filtered through QuadraSil MP metal scavenger cartridges to drop palladium content below 1 ppm, preventing assay interference. The fragment and its elaborated derivatives are stored as 100 mM DMSO-d6 stocks under argon at −80 °C, with a maximum freeze-thaw cycle limit of five to preserve the integrity of the nitro group that is susceptible to reductive metabolism in liver microsome assays. |
Competitive 2-Bromo-5-Nitro-1,3-Thiazole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
2-Bromo-5-nitro-1,3-thiazole (CAS 3034-48-8) possesses an empirical formula of C₃HBrN₂O₂S and a molecular weight of 209.02 g/mol. The isolated solid appears as a pale yellow to off-white crystalline powder with a melting point of 85–89°C (ASTM E324). The heterocyclic architecture places an electron-withdrawing nitro group at the 5-position and a labile bromine atom at the 2-position, establishing a regiochemical motif that permits sequential palladium-catalyzed coupling and subsequent reduction or nucleophilic displacement. This orthogonal reactivity differentiates the material from its 4-nitro regioisomer, where electronic communication between the nitro and bromo substituents is attenuated, and from non-halogenated 5-nitrothiazole, which requires pre-functionalization before carbon–carbon bond formation can occur.
The regiochemistry of the nitro substituent exerts a quantifiable influence on cross‑coupling kinetics. In Suzuki–Miyaura reactions catalyzed by Pd(PPh₃)₄ at a loading of 2 mol% in a DME/water (3:1 v/v) medium at 80 °C, the consumption of 2-bromo-5-nitrothiazole proceeds with a pseudo-first-order rate constant roughly 3–4 times that of the 4-nitro congener under identical base conditions (K₂CO₃, 2.0 equiv). This acceleration is attributed to the para-like alignment of the 5-nitro group relative to the C–Br bond, which stabilizes the developing negative charge on the thiazole ring in the transition state of oxidative addition; the 4-nitro isomer, by contrast, positions the electron‑withdrawing group meta to the reaction center, providing weaker activation. Cyclic voltammetry data on 2-halo-5-nitrothiazoles published in preparative electrochemistry literature confirm a reduction potential shift of approximately +120 mV relative to the 4-nitro series, corroborating the ease of electron injection into the π‑system. This property translates into milder reaction temperatures and shorter cycle times in production-scale Suzuki couplings: while the 4-nitro bromide typically requires 12–16 hours for complete conversion, the 5-nitro isomer routinely reaches an in‑process control specification of ≤0.5 area% starting material by HPLC within 5 hours when employing the same catalyst‑base matrix.
Buchwald–Hartwig amination exhibits a parallel sensitivity to nitro placement. Using Xantphos‑Pd‑G3 (0.5 mol%) and NaOt‑Bu (1.4 equiv) in toluene at 90 °C, 2-bromo-5-nitrothiazole couples with morpholine to produce the corresponding 5-nitro-2-aminothiazole in 94% isolated yield after 3 hours. The 4‑nitro variant, processed under the same conditions, plateaus at 78% conversion, with homocoupling of the thiazole bromide emerging as the major side product. These differences are magnified at scale: the enhanced reactivity of the 5-nitro substrate permits a reduction in palladium inventory, directly lowering the metal‑removal burden during active pharmaceutical ingredient (API) purification and helping the downstream product meet the 10 µg/g Pd limit prescribed by the ICH Q3D guideline for oral drug substances.
In an unlabeled scenario encountered during route scouting, the 5-nitro group also serves as a latent amine. Catalytic hydrogenation over 5% Pd/C (50% water-wet) in ethanol at 25 °C under 3 bar H₂ reduces the nitro function to the primary amine within 2 hours without affecting the 2-bromo handle, provided the hydrogen uptake is terminated promptly at 1.05 equivalents. Extended hydrogenation leads to hydrodebromination; on-stream FTIR monitoring of the 1530 cm⁻¹ NO₂ asymmetric stretch is therefore recommended in kilo‑lab campaigns to arrest the reduction before bromine loss exceeds 0.3%. The resulting 2-bromo-5-aminothiazole is then poised for further diversification—either via acylation under Schotten–Baumann conditions or through a second, sequential cross‑coupling at the C–Br bond.
Differential scanning calorimetry (DSC) executed in accordance with ASTM E537-20 on representative commercial lots reveals an exothermic decomposition onset at 215±5 °C with an associated energy release of approximately 650 J/g. Accelerating rate calorimetry (ARC) data, when available from contract testing laboratories, refine this picture: self‑sustaining decomposition becomes probable above 180 °C under adiabatic conditions. Consequently, bulk drying must be confined to vacuum ovens operated below 50 °C (10 mbar absolute pressure), and the product must not be exposed to surfaces exceeding 150 °C for more than 1 hour. Glass‑lined steel and type 304L stainless steel are suitable materials of construction for storage and reaction vessels; copper and its alloys are contraindicated because thiazoles can coordinate and catalyze ring‑opening pathways.
Moisture sensitivity is moderate but operationally meaningful. At relative humidity above 60%, the compound adsorbs water to levels beyond 0.5 wt% within 4 hours (determined by Karl Fischer titration, Ph. Eur. 2.5.12). Palladium‑catalyzed transformations are exquisitely sensitive to adventitious water, which promotes phosphine oxidation and catalyst decomposition; therefore, a pre‑drying step is mandatory for any lot that has been exposed to ambient air for more than 8 hours. Drying to ≤0.1% water content restores consistent reactivity. The product is shipped in amber glass bottles sealed under argon with a molecular sieve desiccant sachet; once opened, the material should be handled in a nitrogen‑flushed glovebox or stored at 2–8 °C within secondary moisture‑barrier packaging.
Regarding chemical incompatibilities, combination with strong bases such as NaH, KH, or DBU at temperatures above 50 °C can trigger an exothermic event that outpaces laboratory cooling capacity. The bromonitro architecture is also susceptible to violent decomposition upon contact with reducing agents finer than 100 mesh zinc dust or anhydrous hydrazine. Standard operating procedures at toll manufacturers quarantine these reagents to separate process bays and mandate a 2 m minimum separation distance during storage.
Selection among 2‑chloro-, 2‑bromo-, and 2‑iodo‑5‑nitrothiazole hinges on a trade‑off between reactivity, cost, and stability. Oxidative addition rates in palladium‑catalyzed cycles follow the C–I > C–Br > C–Cl trend, with the iodo analogue requiring as little as 0.1 mol% palladium at room temperature for Suzuki couplings. However, the iodo compound (CAS 699-36-7) is typically 5–8 times more expensive per mole and exhibits markedly lower thermal stability (DSC onset 145 °C). The chloro derivative (CAS 24086-50-0) is the least costly but demands elevated temperatures—often 120 °C or above in DMF—and specialized ligand systems such as SPhos or RuPhos to achieve synthetically useful rates, increasing both cycle time and palladium loading. The bromo compound occupies the optimal central position for most medicinal chemistry and agricultural chemical campaigns, delivering robust reactivity with Pd(PPh₃)₄ or XPhos‑based systems while maintaining acceptable exposure margins for thermal risk. Table 1 summarizes key comparative parameters drawn from bulk procurement specifications and thermal safety assessments.
| Parameter | 2-Chloro-5-nitrothiazole | 2-Bromo-5-nitrothiazole | 2-Iodo-5-nitrothiazole |
|---|---|---|---|
| CAS RN | 24086-50-0 | 3034-48-8 | 699-36-7 |
| Typical commercial purity (HPLC, area%) | ≥ 98.0 | ≥ 98.0 | ≥ 97.0 |
| Melting range (°C, ASTM E324) | 48–52 | 85–89 | 98–102 |
| Relative oxidative addition rate (Suzuki, PhB(OH)₂, Pd-0) | 1 (reference) | ~20 | ~200 |
| Approximate bulk cost factor per mole | 1.0 | 2.5–3.5 | 15–20 |
| DSC decomposition onset (°C, ASTM E537) | 250 | 215 | 145 |
| Typical catalyst system for >95% conversion | RuPhos Pd G3, 2 mol%, DMF, 110 °C | XPhos Pd G3, 0.5–1 mol%, THF/H₂O, 70 °C | Pd(PPh₃)₄, 0.1 mol%, dioxane, 25 °C |
Beyond the halide series, additional differentiation arises versus 2-bromo-4-nitrothiazole (CAS 32483-51-3). The 4-nitro isomer places the electron‑withdrawing group adjacent to the thiazole nitrogen, altering the preferred site of nucleophilic attack. Under SNAr conditions with secondary amines, the 4‑nitro isomer undergoes substitution primarily at the 5‑position, whereas 2‑bromo‑5‑nitrothiazole directs nucleophiles exclusively to C‑2, preserving the 5‑nitro group for subsequent reduction. This predictable regiochemical behavior simplifies process analytical technology (PAT) monitoring and reduces the number of trace impurities arising from competing substitution pathways.
In neonicotinoid analog programs, the 5-nitrothiazole scaffold is carried through to the active ingredient core; 2-bromo substitution permits direct Stille coupling with chloropyridinyl stannanes under neutral conditions, avoiding the acidic work‑up that cleaves the labile nitromethylene bridge in the target molecule. Published data for the exact coupling sequence with the specific stannane derivative is limited, yet the synthetic strategy is well precedented on structurally related heterocycles.
Commercial lots supplied to pharmaceutical and agrochemical customers are routinely released against the profile detailed in Table 2. The analytical methods align with compendial standards where cross‑applicable, ensuring data portability across global supply chains.
| Attribute | Acceptance Criterion | Test Method |
|---|---|---|
| Appearance | Pale yellow crystalline powder | Visual (ICH Q6A) |
| Purity (HPLC, 254 nm) | ≥ 98.0 area% | USP <621> / Ph. Eur. 2.2.29 |
| 2,5-Dibromothiazole (over-bromination impurity) | ≤ 0.3 area% | HPLC, RRT 1.4 |
| 2-Bromo-5-aminothiazole | ≤ 0.2 area% | HPLC, RRT 0.6 |
| Water content (Karl Fischer) | ≤ 0.5 wt% | Ph. Eur. 2.5.12 |
| Melting range | 85–89 °C | ASTM E324 |
| Sulfated ash | ≤ 0.1 wt% | Ph. Eur. 2.4.14 |
| Heavy metals (as Pb) | ≤ 10 µg/g | USP <231> |
| Residual Pd (after use in coupling, when tested) | ≤ 10 µg/g | ICP‑MS (ICH Q3D) |
While the compound is not currently the subject of a dedicated pharmacopoeial monograph, the above limits are derived from ICH Q3A guideline thresholds for unspecified impurities and are routinely accepted in Type II drug master file communications. The material is listed on the TSCA inventory and is REACH pre‑registered; procurement from non‑EU suppliers triggers a SVHC screening obligation if shipment volumes exceed 1 tpa.
When the synthetic route designates the thiazole C‑2 position for direct nucleophilic displacement rather than transition‑metal‑catalyzed cross‑coupling, 2-bromo-5-nitrothiazole outperforms its chloro counterpart in rate while avoiding the competing N‑alkylation side reactions occasionally observed with the highly electrophilic iodo congener. Reaction of the bromo compound with potassium phthalimide in NMP at 70 °C proceeds to completion in 4 hours, delivering 2‑phthalimido‑5‑nitrothiazole in 88% yield. The analogous chloro substrate requires temperatures of 130 °C and a phase‑transfer catalyst to reach comparable conversion, and the iodo substrate generates roughly 7% of the ring‑opened thiocyanate byproduct under identical conditions. This balanced reactivity is especially valuable in discovery chemistry groups that employ a universal set of amination conditions across structurally diverse bromoheterocycle libraries: a single parallel protocol—K₂CO₃ in DMSO at 60 °C with 1.2 equiv of amine—delivers consistent yields from pyrazole to thiazole substrates without laborious re‑optimization of temperature or solvent profiles.
Post‑reaction workup is streamlined by the compound’s moderate hydrophobicity (calculated logP 1.8). After aqueous extraction of DMSO or NMP solutions, the crude product can be crystallized directly from 2‑propanol/water (4:1) to reduce the genotoxic impurity 5‑nitro‑2‑hydroxythiazole below the TTC‑based reporting threshold of 1.5 µg/day. This purification protocol has been successfully scaled to 15 kg output in a 200 L glass‑lined reactor equipped with retreat‑curve impeller agitation.
Supply‑chain logistics differ from the chloro and iodo analogues in one further respect: long‑distance transit under uncontrolled temperature conditions (40 °C for 6 weeks in validated shipping studies) does not alter the polymorphic identity of 2‑bromo‑5‑nitrothiazole (Form I remained unchanged by XRPD), whereas the iodo derivative shows perceptible amorphization and color darkening. This physical robustness reduces the burden of on‑arrival re‑qualification at satellite manufacturing sites and supports just‑in‑time inventory models for CDMOs running multiproduct manufacturing campaigns.
